Summary:
In youth-onset type 2 diabetes (African American adolescents), metformin alone versus metformin plus liraglutide significantly altered systemic and gut microbiome composition and metabolomic profiles over 3 months compared to metformin monotherapy (metformin 1000 mg daily vs metformin 1000 mg daily plus liraglutide 1.8 mg daily), though it was associated with variable effects on glycemia and potential gastrointestinal side effects with liraglutide.
| PICO | Description |
|---|---|
| Population | African American youth diagnosed with type 2 diabetes (youth-onset T2D). |
| Intervention | Combination therapy of metformin 1000 mg daily plus liraglutide up to 1.8 mg daily over 3 months. |
| Comparison | Metformin monotherapy at 1000 mg daily over 3 months. |
| Outcome | Combined treatment led to significant shifts in gut microbial species abundance and plasma metabolite profiles, correlating with modest improvements in glycemic control. However, liraglutide addition was associated with gastrointestinal side effects and variable metabolic responses. |
Source: Sophia B Glaros, et al. “Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.” Read article here.
